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Background: Height is a strong prognostic factor in cystic fibrosis (CF) and is usually compared to reference values of healthy children by
expressing height as a z-score height-for-age (HFA). However, HFA does not take into account a potential delay in bone age (BA) and the genetic
potential of the child and could therefore result in misclassification of short stature.
Methods: In 169 children with CF height, BA and target height (TH) were assessed. HFA, height for bone age (HBA), HFA adjusted for target
height (HFA/TH) and HBA adjusted for target height (HFA/TH) were determined and children were categorized according to these four methods.
Results: Mean z-scores of the four methods ranged from −0.1±0.8 (HBA/TH) to −0.5±1.0 (HFA). Prevalence of short stature (z-score b−2 SD)
determined by HFA (8%, n=14) was higher than when HBA, HFA/TH (both 5%, n=8) and HBA/TH (1% n=1) were applied.
Conclusion: The method used to classify height affects outcome on a group level and for individual patients. Target height and bone age are likely
to have added value in the interpretation of height in patients with CF.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pediatric patients; Body-height; Age determination by skeleton; Target height1. Introduction
Over the years, survival of patients with cystic fibrosis (CF) has
improved significantly [1–4], especially in pediatric patients [5].
The increased survival is mainly the result of aggressive treatment
of lung disease and increased attention to nutritional status [1,6,7].
Alongwith pulmonary function, nutritional status appears to be an
important prognostic indicator in patients with CF because it is a
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doi:10.1016/j.jcf.2011.03.003young age is significantly associated with pulmonary function at a
later age [8]. In the 19,000 patients of the US-CFF registry it was
observed that both boys and girls with a height below the 5th
percentile at age 5 and 7 years had a much higher risk of death
compared to taller patients [9]. Therefore, early detection and
timely intervention of reduced height is essential to optimize
growth and to reduce mortality in children with CF.
In clinical practice height is compared to reference values of
healthy children based on chronological age, by converting it tostra@umcutrecht.nl (T. Hoekstra), H.P.J.vanderdoef@umcutrecht.nl
d by Elsevier B.V. All rights reserved.
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widely accepted, it has limitations. Firstly, CF is associated with
a delay in skeletal maturation [10,11], particularly in adoles-
cence [12]. In these situations, the use of HFA might result in
misclassification of height. Secondly, height is a hereditable
trait depending on the height of its biological parents and also
the child's own development. In HFA calculation no adjustment
is being made for this genetic component.
Therefore, measures taking both maturation and the genetic
potential of the child into account might provide a more
appropriate method to monitor growth of a child with CF. The
aim of the current study was to investigate the levels of
agreement between HFA, height for bone age (HBA), height
adjusted for target height (HFA/TH) and height for bone age
adjusted for target height (HBA/TH) in both the total group of
pediatric patients with CF and in pediatric patients with short
stature (z-score b−2 SD).2. Methods
2.1. Study population
In a cross sectional study 207 unselected Dutch children with
proven CF were recruited from the outpatient clinic of the
Wilhelmina's Children's Hospital, University Medical Centre
Utrecht, The Netherlands. All children had a positive sweat test
and/or the presence of two CF mutations, combined with
clinical signs of CF. Patients were excluded if a hand-wrist
x-ray was not available at the time of analysis (37 children) or if
there was incomplete information of the parental height (1
child). Therefore, data of 169 children were included in the final
analyses.
The included patients were in a clinically stable condition at
the time of the measurements. The measurements were part of
the annual check-up and performed in order to improve the
standard health care. All patients, or parents when it concerned
young children, gave informed consent to collect the data in a
database. The study was performed according to the guidelines
of the medical ethics board of the University Medical Centre
Utrecht. Data was collected between May 2008 and July 2009.2.2. Bone age assessment
An x-ray was performed of the left hand-wrist. Bone age was
determined by themethod ofGreulich and Pyle [13] by a pediatric
radiologist and an educated researcher (C.H.)whowere blinded to
clinical features. If the hand x-ray was not corresponding to one
standard, bone age was defined as age between two standards.
When the assessment of bone age varied less than 1 year between
the two observers the bone age was defined as the average of both
values. In situations where it varied more than 1 year, the hand-
wrist x-ray was interpreted by a third independent pediatric
radiologist. If the difference of outcome was less than 1 year, the
average of the two values which were most comparable was
defined as bone age. A difference of more than 1 year was
discussed by two interpreters until consensus was reached.2.3. Target height assessment
During the outpatient visits, the biological parents of the
patients were measured with a stadiometer to the nearest 0.5 cm
(Holtain, Crymich, UK) and expressed in centimeters. Missing
heights were completed by contacting the parent by telephone
(n=6). Target height was defined as height at the age of
18 years and calculated by using the following formulas: target
height for boys=44.5+0.376× father height+0.4111×mother
height, target height for girls=47.1+0.334× father height+
0.364×mother height. Z-score target height was calculated
using the formulas: z-score TH boys=(TH−183.8) /7.1. Z-
score girls TH=(TH−170.7) /6.3. Formulas for calculating the
TH are based on a nationwide growth study in The Netherlands
[14]. In 2010 revised growth charts and formulas were
published based on most recent data. These formulas adjust
for genetic potential in children with discordant parents [15].
2.4. Clinical measurements
Pulmonary function was assessed as forced expiratory
volume in 1 s (FEV1). FEV1 was obtained from maximal
expiratory flow volume curves (Masterscreen; Viasys Health-
care, Höchberg, Germany) and expressed as percentage of the
predicted height and sex (FEV1% pred) [16]. A 3-day food
intake diary was used to estimate mean daily intake, expressed
as a percentage of the recommended daily caloric intake for
Dutch children [17] and protein and fat intake expressed as a
percentage of the energy-intake.
Height was measured with a stadiometer to the nearest 0.5 cm
(Holtain, Crymich, UK) and expressed in centimeters.Weight was
measured using a digital weight scale to the nearest 0.1 kg. The
ratio of weight/height2 (kg/m2) was used to calculate the body-
mass-index. Height and weight were compared with reference
values forDutch children by converting them to z-score height-for-
age, weight-for-age, weight-for-height and body-mass-index,
using specialized software (Growth Analyses 3, 2001–2004,
Dutch Growth Foundation). For non-Dutch children height was
compared to reference values of their nationality. Children with
one non-Dutch parent were analyzed to conform Dutch growth
charts. Height according to bone age was determined by using
bone age instead of chronological age. Both HFA and HBA were
additionally adjusted for target height by subtracting z-score TH
from HFA and HBA respectively as previously described in the
Dutch Consensus Guideline [18].
The z-scores for height, defined by the four methods were
classified into four categories of nutritional status: z-score≥0,
z-scoreb0 and≥−1, z-score b−1 and≥−2 and z-score b−2 (i.e.
short stature).
2.5. Statistical analysis
The student's t-test for independent samples and the Pearson's
chi-square test were performed to compare baseline differences
between boys and girls. For the total group and for boys and girls
separate clinical characteristic and anthropometric variables were
reported. Comparison between the outcomes of z-score height
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between HFA and height according to bone age, height adjusted
for target height and height according to bone age and adjusted for
target height was assessed by calculating the weighted kappa
coefficient. Kappa coefficients that are b0.20, 0.21–0.40, 0.41–
060, 0.61–0.80 and 0.80–1.00 were considered to indicate poor,
fair, moderate, good and very good agreement respectively [19].
Because of the marked changes in anthropometry during puberty
[20] and reported delayed bone age particularly in adolescents
[10,11], the data was divided into two different age groups:
b11 year and ≥11 year to investigate the difference between
height expressed as height-for-age and height for bone age.
Data management was performed by using Excel computer
software (Microsoft Excel, 2002). Statistical analyses were
performed by using the Statistical Package for the Social Sciences
Computer Software (SPSS Inc., version 17 for Windows,
Chicago, IL). The weighted kappa coefficients were calculated
using SAS (version 9.1; SAS Institute Inc, Cary NC, USA).
3. Results
3.1. Study population
In this study 169 children with proven CF were included. The
study population consisted of 162 Dutch children, 2 Moroccan, 3
Turkish and 2 children of another nationality. The best recorded
forced expiratory volume in 1 s (FEV1) during the last year ranged
from 25 to 128%. The mean FEV1 was 90% (±20%). After
classifying the outcome of the pulmonary function test, 72% had a
normal pulmonary function (FEV1≥80% predicted), 20% a
moderate pulmonary function (FEV1b80% and ≥60% pre-
dicted) and 8% an impaired pulmonary function (FEV1b60%
predicted). The mean daily energy intake, expressed as a
percentage of the recommended daily caloric intake for Dutch
children, ranged from 56 to 159%. The average protein and fat
intake was respectively 13% (±2%) and 35% (±6%) of the
energy-intake. Boys and girls were similar in age, FEV1%,
energy-, protein and fat intake and z-scores nutritional status.
All but 8 patients were pancreatic insufficient and treated
with pancreatic enzyme replacement therapy. The average
calculated z-scores for all parameters of the nutritional status
(height and/or weight containing data) were below zero in both
the whole group as well as in boys and girls separately. The z-
scores height were for HFA: −0.5 (±1.0), for HBA: −0.2 (±0.9),
for HFA/TH: −0.3 (±0.9) and for HBA/TH: −0.1 (±0.8)
respectively.
In Fig. 1, a scatter plot of chronological vs. bone age is
presented. In 63% of the patients a delay in bone age compared
to chronological age was observed with a mean delay of
2.7 months. Of the study population, 18% had a delay of more
than 1 year.
After dividing the population into two different age groups:
childrenb11 years and adolescents≥11 years, children showed
an average delay in bone age of 3.4 months and adolescents of
2.4 months. The z-scores for height for chronological age and
height for bone age were comparable for children and
adolescent, respectively −0.54 (±1.07) vs. −0.44 (±0.98) forchronological age and −0.17 (±0.98) vs. −0.26 (±0.90) for
bone age.
This study found an average height of respectively 183 cm±
7.5 cm (z-score −0.1) and 169 cm±6.9 cm (z-score −0.1) for
fathers and mothers of the patients. The baseline characteristics
are summarized in Table 1, the height characteristics in Table 2.
3.2. Comparison of height for chronological age and bone age
with and without adjustment for target height
The z-scores for height, defined by the four methods were
classified into four categories: z-score≥0, z-scoreb0 and ≥−1,
z-score b−1 and ≥−2 and z-score b−2 (i.e. short stature). In
Table 3 the distributions over these categories when using the
adjusted methods (i.e. HBA, HFA/TH and HBA/TH) are
compared with the distribution when the z-score HFA was
applied. Agreements between outcomes are bold in text and
underlined. The highest level of agreement with HFA was
observed for the classification using the z-score HFA adjusted
for target height. In 104 children (=62%) these two methods
resulted in the same classification (weighted kappa 0.56). For
45 children (=27%) using HFA/TH the two methods resulted in
a higher z-score category than when HFA was used. For HBA in
92 children (54%) agreement was observed with classification
according to HFA (weighted kappa 0.47). The largest deviation
from the categorization using HFA was observed for HBA/TH,
the measure using bone age and adjusted for target height
(weighted kappa of 0.26). For only 47% of the children (n=80)
those two methods resulted in the same category.
For some individual children differences were distinct. Four
children fell in the highest z-score category (i.e. z-score≥0)
when HBA/TH was applied while they were categorized in the
lowest z-score category (i.e. short stature) when HFA was used.
Only one child was defined as having short stature by HFA and
HBA/TH. Overall, height expressed as HFA resulted in lower z-
scores in comparison to the other three methods.
Performing the analysis separately for boys and girls yielded
comparable results (data not shown).
4. Discussion
In our population of patients with CF low to moderate
agreement was found between z-score height-for-age and z-
scores height-for-age adjusted for target height and height for
bone age with and without adjustment for target height. In
general, height expressed as height-for-age resulted in lower z-
scores and therefore more children were defined as having short
stature, in comparison to the other methods. As far as we know
no other studies described and compared height for bone age
and target height in pediatric patients with CF.
Correction for bone age and/or target height led to discrepant
prevalence estimates of short stature (z-score b−2). Compared
with the HBA and HFA/TH method, the HFA method
overestimated short stature in respectively 8 and 10 patients
and in 13 patients according to the HBA/TH method. Although,
according to the HBA and HFA/THmethods, respectively 2 and
4 children were classified as having short stature while the z-
Fig. 1. Chronological age vs. bone age in 169 children with Cystic Fibrosis Dots under the line represented a delay in bone age.
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stature for only 1 child according to all four methods.
Mid-parental heights are widely used to help assess an
individual child's growth but there may be limitations when they
make no allowance for extremes of parental height while
children of very tall or short parents tend to be less extreme in
their height. Talma et al. took these limitations into account by
adjusting for genetic potential in children with discordant
parents [15]. The importance of accounting for genetic potential
when evaluating stature is supported by a large cross sectional
study of 3306 patients with CF, aged 2–18 years. In this study it
was concluded that without adjustment of genetic potential, the
prevalence of short stature is underestimated in children with tall
parents and overestimated in children with short parents [21].
The average z-score for height-for-age in our population was
−0.5 which corresponds with other studies, in which average
height in children with CF ranged from 25th–44th percentile (z-
score ≈−0.2 to −0.7) [8,22–24]. Short stature was defined as z-
score b−2 while some other studies defined short stature as
height b5th percentile (≈z-score −1.7). In our population we
observed in 11.8% of the children a z-score HFA below the 5th
percentile. Consistent with these findings are the results of two
cross-sectional studies among respectively 788 and 4577
children with CF where z-scores beneath the 5th percentile
for 12.2%–19.2% of the population were described [22,25].
Our study showed that 66% of the children had a z-score height-
for-age below the average of their calculated z-score target
height while Zhang et al. reported a z-score height-for-age
below the average of their parental height percentile in 80% of
the children with CF [21]. This difference might partly be
explained by differences in the way parental height was
estimated. In our study parental height was measured, while
Zhang et al. used self-reported height. It is known that selfreported height is generally overestimated [26], resulting in
lower z-scores for target height in their children.
Bone age was performed according to the method of
Greulich and Pyle. This method is relatively easy to perform
and has been shown to have a good reproducibility [27]. It has
been questioned whether this method is still valid in modern-
day children as the method has remained unchanged for more
than 50 years. However, it was shown to be still applicable in
Dutch Caucasian children and adolescents [28]. The children
from the study of Greulich and Pyle were from upper middle
class homes which might explain why the reference bone ages
in the atlas have been found to be advanced relative to almost all
general populations studied since then.
In 63% of the patients a delay in bone age compared to
chronological age was observed with a mean delay of
2.7 months. These results are comparable with the data from a
large study of healthy Dutch children [28]. To our knowledge,
only two other studies investigated bone age in children with
CF. Buntain et al. reported a delay of bone age of 2.0 months in
children with CF which is comparable with our results.
However, they observed a delay of bone age of 9.8 months in
adolescents with CF which is more pronounced than our results
[12]. Besides the general disease state, they implied that
nutritional status had a great impact on skeletal maturation. Our
study showed a slightly better nutritional condition of the study
population in comparison to the adolescents in the study of
Buntain et al. (z-score weight −0.57 (±0.79) vs. −0.79 (±0.88),
z-score height-for-age −0.44 (±0.98) vs. −0.91 (±0.82)
respectively). Probably, these differences in nutritional status
may explain the difference in skeletal maturation. Another study
from 1964 described that bone age was delayed by more than
24 months in a quarter of the adolescents with CF [29]. This
study is from a time when there was less attention for nutritional
Table 1
Baseline characteristics of the 169 patients with cystic fibrosis.
Total group (n=169) Boys (n=90) Girls (n=79) P a
Average±SD Average±SD Average±SD
Age (years) 11.1 (3.7) 11.6 (3.7) 10.7 (3.6) 0.11
Bone age 10.9 (3.7) 11.4 (4.0) 10.3 (3.7) 0.06
Calculated TH in cm 177(8) 183(4) 170(4) 0.00
Calculated z-score TH −0.1 (0.6) −0.2 (0.6) −0.1 (0.6) 0.75
BMI 17.0(2.2) 17.2 (2.2) 16.9 (2.3) 0.38
Z-score BMI −0.3 (0.8) −0.3 (0.7) −0.4 (0.9) 0.31
Z-score WFA −0.5 (0.9) −0.5 (0.7) −0.5 (1.0) 0.93
Z-score WFH −0.3 (0.7) −0.2 (0.7) −0.3 (0.8) 0.51
Z-score HFA −0.5 (1.0) −0.6 (0.9) −0.4 (1.1) 0.35
Energy intake (kcal) (n=139) 2257(539) 2408(572) 2080(438) 0.00
Energy intake (% RDI) 103(20) 101(21) 104(19) 0.40
Protein intake (En %) 13(2) 13(3) 13(2) 0.82
Fat intake (En %) 35(6) 35(6) 35(5) 0.47
CFA (n=137) 90(8) 90(7) 89(8) 0.93
FEV1 (% pred) 90(20) 91(19) 89(20) 0.53
CFTR genotype b
Severe 154 (93%) 82 (93%) 72 (92%) 1.00 c
Homozygous Δ F508 (%) 105 (63%) 58 (66%) 47 (60%) 0.89 c
Mild 12 (7%) 6 (7%) 6 (8%)
Abbreviations:
TH: target height
BMI: body mass index, calculated as kg/m2
WFA: weight for age
WFH: weight for height
HFA: height for age
% RDI: % recommended daily intake
En %: percent of energy intake
CFA: coefficient of fat absorption
FEV1% pred=forced expiratory volume in 1 second% predicted
SD: standard deviation
a Student-t test between boys and girls.
b Genotype of 3 patients was not identified (2 boys).
c Pearson's chi-square test (severe genotype or ΔF508 homozygous vs. mild genotype).
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status. Therefore, probably, the differences in outcome of bone
age between this study and more recent studies can be attributed
to the increased attention to nutritional status over the years.
Since a poor nutritional status may attribute to the delay in bone
age it might not be appropriate to adjust for bone age in clinical
settings. However, children with a delayed development might
have a prolonged growth potential. More research is needed to
be able to draw conclusions on the most valid representation of
height.Table 2
Height characteristics of the 169 children with cystic fibrosis (CF) (90 boys).
Z-score categories (%) HFA HBA HFA/TH HBA/TH
≥0 31 41 36 47
b 0 and ≥−1 38 38 41 40
b−1 and ≥−2 22 16 18 13
b−2 8 5 5 1
Abbreviations:
TH: target height
HFA: height for chronological age
HBA: height for bone age
HFA/TH: HFA adjusted for TH
HBA/TH: HBA adjusted for THAn important implication can be drawn from the deviation in
classifying nutritional status according to the four methods.
Current guidelines describe that children with a reduced body-
mass-index and/or weight-for-height need a high-energy diet, if
necessary supplemented with high-energy drinks and/or enteral
tube feeding [30,31]. Weight-for height and BMI calculated
using unadjusted height might result in an underestimation of
the impact of CF associated malnutrition because children with
a short stature and a normal weight will still have normal body-
mass-index and/or weight-for-height z-scores. This might result
to an inadequate nutritional treatment in this specific group.
This stresses the need to take a delay in skeletal maturation and
the genetic contribution into account to evaluate height as part
of the nutritional status assessment.
This study did not include puberty status measurements,
because this data was not available. The results of this study
may have been affected by this, as the study results were
compared with reference values collected in healthy children
with normal puberty development.
The main drawback of the study is that it concerns a cross
sectional analysis. It is not justified to make strong conclusions
regarding clinical implications based on findings as the study
design is cross-sectional. A golden standard for expressing
Table 3
Comparison of the classification of height expressed as z-score height for age (HFA) with z-score height for bone age (HBA), z-score HFA adjusted for target height
(HFA/TH) and HBA adjusted for TH (HBA/TH) in 169 children with CF.
HBA HFA/TH HBA/TH
HFA ≥0 b0 and ≥−1 b−1 and ≥−2 b−2 ≥0 b0 and ≥−1 b−1 and ≥−2 b−2 ≥0 b0 and ≥−1 b−1 and ≥−2 b −2
≥0 40 12 1 0 43 9 1 0 38 12 3 0
b 0 and ≥−1 26 31 7 0 15 42 6 1 26 32 6 0
b−1 and ≥−2 3 18 15 2 2 18 15 3 12 17 9 0
b−2 1 3 4 6 0 2 8 4 4 5 4 1
Data are presented as numbers of children in the specific group.
The bold underlined printed numbers show the agreement in classification of height.
277J.W. Woestenenk et al. / Journal of Cystic Fibrosis 10 (2011) 272–277height is not available and it is thus unclear which method
would be preferable in clinical practice in children with CF.
However, we observed that the method used to classify height
affects the outcome on a group level and for individual patients.
In current guidelines unadjusted height is being used which
might result in misclassification of short stature. The commonly
used method may thus not be the most appropriate method.
However, more research is needed before conclusions can be
drawn on which method is the most valid method. Longitudinal
analyses are necessary to relate changes over time in these
measures with clinical outcomes such as pulmonary status.
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